BioLineRx (BLRX) Cash & Current Investments (2023 - 2025)
Historic Cash & Current Investments for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $25.2 million.
- BioLineRx's Cash & Current Investments fell 1357.76% to $25.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.2 million, marking a year-over-year decrease of 1357.76%. This contributed to the annual value of $19.6 million for FY2024, which is 5450.06% down from last year.
- As of Q3 2025, BioLineRx's Cash & Current Investments stood at $25.2 million, which was down 1357.76% from $28.2 million recorded in Q2 2025.
- Over the past 5 years, BioLineRx's Cash & Current Investments peaked at $43.3 million during Q1 2023, and registered a low of $19.6 million during Q4 2024.
- In the last 3 years, BioLineRx's Cash & Current Investments had a median value of $28.2 million in 2024 and averaged $30.6 million.
- Data for BioLineRx's Cash & Current Investments shows a peak YoY increase of 1234.21% (in 2024) and a maximum YoY decrease of 5450.06% (in 2024) over the last 5 years.
- Over the past 3 years, BioLineRx's Cash & Current Investments (Quarter) stood at $43.0 million in 2023, then crashed by 54.5% to $19.6 million in 2024, then grew by 28.88% to $25.2 million in 2025.
- Its Cash & Current Investments was $25.2 million in Q3 2025, compared to $28.2 million in Q2 2025 and $26.4 million in Q1 2025.